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Summary
Objectives: To assess whether glucosamine (GlcN), an oral supplement commonly taken to relieve the symptoms of osteoarthritis, modulates
the immune and inﬂammatory responses to joint injury in organs proximal to GlcN absorption; namely, the liver and the gut-draining lymph
nodes.
Method: Using a papain-injected knee mouse model, standard histological methods were used to validate our model and document the impact
of GlcN (100 mg/kg/day) on groups of C57BL/6 mice (n¼ 5). Circulating inﬂammatory cytokines were assessed by Luminex-based immuno-
assays and the relevance of this cytokine proﬁle on proteoglycan biosynthesis evaluated using a patellar-cartilage assay. Real-time PCR was
used to document the role of the liver in cytokine production. Finally, we appraised the activation of mesenteric lymph nodes (MLNs) lympho-
cytes by ﬂow cytometry.
Results: Papain signiﬁcantly degraded the proteoglycans in the injected knees by 2 days. Cartilage proteoglycan content was signiﬁcantly
higher in GlcN-treated, papain-injected knees at Day 14. The peak concentration of serum pro-inﬂammatory cytokines occurred earlier and
decreased sooner in the injected, GlcN-supplemented mice; this trend was in agreement with the expression of these factors by the liver.
GlcN did not alter the percentage of MLN populations but accelerated their activation.
Conclusions: Oral GlcN alters the physiology of the liver and MLNs, which in turn, could indirectly alter the biology of the injured joint.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Arthritis, a leading cause of disability, imposes a large ﬁnan-
cial and social burden on society1. Glucosamine (GlcN) fre-
quently with chondroitin sulfate has gained popularity as
a natural, over-the-counter remedy for osteoarthritis (OA).
In recent surveys it is taken by 8% of educated, middle
and high income Canadians2 and in the USA by 15% of
the population who are multi-supplement users and who
also are largely older, educated and upper and middle
class3. Doubt has been cast on the effectiveness of oral
GlcN to treat the symptoms, mainly pain, of OA. The large
National Institutes of Health sponsored GAIT study using
500 mg three times a day doses of GlcNHCl did not ﬁnd
any signiﬁcant effect on symptoms or on joint space narrow-
ing4. However, in two large European industry sponsored
trials of GlcN sulfate as a 1500 mg/day bolus a signiﬁcant*Address correspondence and reprint requests to: T. R. Oegema,
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1014effect on symptoms was found5,6. These 3 year long study
also measured joint space and reported GlcN sulfate pre-
vented the lost of signiﬁcant joint space5,6 and had fewer
knee replacements after up to 8 years of follow-up7. GlcN
sulfate was without effect on symptoms in OA of the hip8.
Recently several non-industry funded GlcNsulfate or
GlcNHCl studies of knee OA have found little or no effect9.
Therefore, the effectiveness of GlcN in general and possible
differences between GlcNHCl and GlcNsulfate are areas
of active disagreement9e11. This is in contrast to studies
in animal models of OA where GlcN has a positive effect
in maintaining cartilage structure or restoring proteoglycan
content12e14.
Since GlcN use is controversial, understanding if, when,
and by what mechanism(s) GlcN works, especially in main-
taining or restoring cartilage structure, is important if GlcN is
to remain a viable therapeutic option. GlcN does not act by
increasing chondroitin sulfate and keratan sulfate synthe-
sis15. However, in vitro GlcN abrogates many aspects of
inﬂammation in chondrocytes and synovial ﬁbroblasts16.
This includes: down regulation the response to interleukin
(IL)-117 and reactive oxygen species18 and inﬂuences pro-
liferation and matrix production19. Because of its signiﬁcant
1015Osteoarthritis and Cartilage Vol. 17, No. 8ﬁrst-pass metabolism14 peak serum levels of GlcN in ani-
mals and humans dosed orally are lower than those typi-
cally needed to induce positive responses in vitro20. In
humans, the recommended dosage of either 500 mg t.i.d.
or 1500 mg bolus results in low peak serum GlcN levels
(<10 mM)20e22. Laverty et al. found the levels of GlcN hy-
drochloride and GlcN sulfate in synovial ﬂuid in horses to
be well below that of the serum levels (w0.1e0.7 mM)23,
but approached serum levels if the joint was inﬂammed by
pretreatment with lipopolysaccharide24. This is similar to
the GlcN levels in synovial ﬂuid from a human inﬂamed
OA joint22 by not normal joints, These concentrations are
at the low end of concentrations that typically give a biolog-
ical effect in vitro in chondrocytes16,25. This raises the pos-
sibility that oral GlcN may also act through alternative
mechanisms.
Given the typically low circulating levels of GlcN, we rea-
soned that the liver is exposed to much higher levels of
GlcN than other tissues (due to its proximity to the site of
GlcN absorption and the hepatic portal system) and may
have a modulated acute-phase response to joint injury as
a consequence and this might also effect other near-by
structures such as intestinal draining mesenteric lymph no-
des (MLNs). To test these ideas, we used a mouse model of
papain-induced joint damage and repair adapted from van
den Berg26 to determine whether GlcN supplements alter
the inﬂammatory response to joint injury in the liver and in-
testinal draining lymph nodes. We assessed circulating
levels of inﬂammatory cytokines interferon-g (IFN-g), tumor
necrosis factor-a (TNF-a), granulocyte macrophage colony-
stimulating factor (GM-CSF), IL-6, IL-12, macrophage in-
ﬂammatory protein (MIP)-1a, and IL-1b. Further, we used
real-time PCR to determine if the production of these factors
by the liver was inﬂuenced by either joint injury and/or GlcN.
Finally, we investigated whether lymphocyte populations in
the MLNs near the gut were altered possibly resulting in
a modiﬁed immune response to joint damage.Materials and methodsMOUSE STRAINSGroups of ﬁve 10-week old female C57BL/6 mice (Jackson Laboratory,
Bar Harbor, ME) were used in this study and maintained according to the
standards of the Institutional Animal Care and Use Committee of Rush Uni-
versity Medical Center. After 1 week of acclimation, the mice received a 6 mL
intra-articular injection of either a 1 U/mL of L-cysteine-activated papain in
phosphate buffered saline (PBS) (Sigma, St. Louis, MO) or and L-cysteine
in their left knee joints26. All mice were fed a powdered Rodent Diet (Harlan,
Bartonville, IL), with the ‘supplemented’ groups receiving 100 mg/kg/day D-
glucosamine hydrochloride (Pfanstiehl Laboratories, Waukegan, IL). Food
uptake was monitored by the amount of diet consumed and weight of the an-
imals monitored weekly. The starting weight of the mice was 18.2 0.75 g
std dev. Organs and serum were harvested 0, 2, 7, 14, and 21 days after
the intra-articular injections. The Day 0 group did not receive either a papain
injection or GlcN and was the control group.SERUM COLLECTIONBlood collected via cardiac puncture under isoﬂurane anesthesia was co-
agulated for 1 h on ice centrifuged at 1000 g for 10 min at 4C and the se-
rum samples were stored at 80C until analysis and thawed no more than
twice. Animals were immediately sacriﬁced post blood draw by cervical dis-
location and the liver, MLNs, and knee joints harvested.HISTOLOGYKnee joints were immediately ﬁxed in 10% formaldehyde for 5 days and
were then decalciﬁed with 10% formic acid, trimmed of excess soft tissue,
and washed extensively with water. After multiple ethanol washes, followed
by dioxane, the joints were parafﬁn embedded. Eight-micron sections were
prepared and stained with Safranin-O and fast green to assess proteoglycandensity. The density of the Safranin-O stain was quantiﬁed27 in the middle
layer cartilage. Images were captured of the mouse femoral weight-bearing
cartilage using a Nikon Eclipse E800 microscope (Nikon, Melville, NY) equip-
ped with a green ﬁlter and the Metamorph software package. After being pro-
cessed into gray scale using the Quantity One (v4.5.2) software package
(Bio-Rad), the pixel density of ﬁve equal random areas in the mid-zone ma-
trix was measured between cells in the femoral weight-bearing region. The
densities of the ﬁve random areas were averaged for each sample, and
these values averaged across the group and the groups compared by un-
paired Student’s t test.CYTOKINES MEASUREMENTSSerum cytokine levels were measured using the Bio-Plex Mouse Cyto-
kine Panel according to the manufacturer’s recommendations. The panel
included: interleukins-1a (IL-1a), -1b (IL-1b), -2 (IL-2), -3(IL-3), -4 (IL-4), -5
(IL-5), -6 (IL-6), -7 (IL-7), -8 (IL-8), -10 (IL-10), -12 (IL-12 p40 and p70), -13
(IL-13), -17 (IL-17), Eotaxin, G-CSF, GM-CSF, IFN-g, KC (CXCL1), MIP-1a
and b, RANTES, and TNF-a. Cytokine concentrations were calculated
from ﬁve-parametric regression analysis standard curves determined by
the Bio-Plex Manager software. Statistical analyses were then performed
on this data set, as described below.REAL-TIME PCRLivers collected in tissue cassettes and snap frozen in liquid nitrogen at
the time of harvest were pulverized under liquid nitrogen, weighed, and
RNA from approximately 20 mg of each liver extracted using TRIzol reagents
(Invitrogen Life Technologies, Carlsbad, CA). Total RNA consistently yielded
Abs260/Abs280 ratios of 1.55e2.0. After DNase digestion using RNase-free
DNase I (Invitrogen, Carlsbad CA) 5 mg of total RNA was reverse transcribed
using Invitrogen SuperScript II (Invitrogen, Carlsbad CA) and stored
at 20C until real-time PCR was performed.
Murine PCR primers (Integrated DNA Technologies, Coralville, IA) were
designed using the Primer 3 software package (Whitehead Institute for Bio-
medical Research, Cambridge MA), with amplicons ranging from 75 to 150
base pairs with TM averaging 60
C. Real-time PCR primer sequences are
as follows: b-actin e (F) 50-CGGCTACCACATCCAAGGAA-30, (R) 50-AGA
GGGAAATCGTGCGTGAC-30; TNF-a e (F) 50-CCGACTACGTGCTCCT
CACC-30, (R) 50-GCTGAGTTGGTCCCCCTTCT-30; MIP-1a e (F) 50-ATG
GAGCTGACACCCCGACT-30, (R) 50-GACACCTGGCTGGGAGCAAA-30;
IL-1b e (F) 50-TTGACGGACCCAAAAGATG-30, (R) 50-AGAAGGTGCTCAT
GTCCTCA-30; IL-6 e (F) 50-ATGAAGTTCCTCTCTGCAAGAGACT-30, (R)
50-CACTAGGTTTGCCGAGTAGATCTC-30; GM-CSF e (F) 50-ACTTTTCCT
GGGCATTGTGG-30, (R) 50-CCAGGAGGTTCAGGGCTTCT-30; IL-12 e (F)
50-GATGTCATCTTCTTCAGGCGTGTCA-30, (R) 50-TTATGTTGTAGAGGT
GGACTGGACTC-30; IFN-g e (F) 50-GTGATTGCGGGGTTGTATCT-30, (R)
50-CACATTCGAGTGCTGTCTGG-30; RANTES e (F) 50-CGCTTTGGAGTT
GAGCTAGG-30, (R) 50-GGAGCACTGAGGGTCTTTCA-30.
Real-time PCR assay was performed on a Cepheid SmartCycler system
using Platinum Quantitative PCR Supermix-UDG (Invitrogen, Carlsbad CA),
with the PCR conditions optimized for annealing time and temperature. Cycle
threshold (Ct) values were then assessed relative to an internal housekeep-
ing gene (b-actin) and normalized to the Day 0 non-injected control using the
2DDCt method28. Each sample was repeated in duplicate and averaged.FLOW CYTOMETRY OF MLN CELLSMLNs were harvested from each mouse, disaggregated through a wire
mesh screen, and centrifuged for 5 min at 800 rpm on a Dynac III tabletop
centrifuge (BD, Franklin Lakes, NJ). The cells were then resuspended in
50% dulbecco’s modiﬁed eagle’s medium (DMEM), 40% fetal bovine serum
(FBS) 10% dimethyl sulfoxide and stored at 80C until evaluation by ﬂow
cytometry.
Samples were thawed and resuspended in warm DMEMþ 10% FBS,
washed, and incubated with 1 mL of 0.5 mg/mL ﬂuorescein isothiocyanate
(FITC)-conjugated hamster anti-mouse CD69 (Very Early Activation Antigen)
monoclonal antibody (BD Pharmingen, San Diego, CA) to test for activation
state. The MLN lymphocytes from each mouse were stained for the following
markers (all antibodies used at 0.2 mg/mL and from BD Pharmingen, San
Diego, CA, unless speciﬁed): cytotoxic T-lymphocytes, thymocytes, and Nat-
ural Killer T-Cells (NK-T) cells using r-phytoerythrin (R-PE)-conjugated ham-
ster anti-mouse CD3e monoclonal antibody, T helper cells using R-PE-
conjugated rat anti-mouse CD4 (L3T4) monoclonal antibody, T cytotoxic
cells using CD8-b (H35-17.2): sc-20041 (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA), B-lymphocytes using R-PE-conjugated rat anti-mouse
CD45R/B220 monoclonal antibody, granulocytes using R-PE-conjugated
rat anti-mouse Ly-6G and Ly-6C (Gr-1) monoclonal antibody, lymph node
homing receptor using R-PE-conjugated rat anti-mouse CD62L (L-selectin,
LECAM-1, Ly-22) monoclonal antibody, and macrophages using rat anti-
mouse F4/80 antigen: biotin (AbD Serotec Oxford, UK). Some cells were
1016 S. Panicker et al.: A mouse model of glucosamine actionalso pooled, from each ﬂow cytometry experiment, to create a control spec-
imen (for background subtraction) and single ﬂuorescent color (CD69-FITC
and CD3-PE) for color compensation. The labeled cells were then washed
and streptavidin, R-phycoerythrin conjugate (SA-PE) (Invitrogen, Carlsbad,
CA) was added to the background tubes and biotinylated samples 30 min
at 4C. The labeled cells were washed, ﬁxed (2% formaldehyde in
1PBS) and counted on the BD Biosciences, San Jose, CA FACS Canto
II12. Data was collected from 10,000 cells (‘‘events’’) per sample. In order
to identify these cells, cell size and granularity were used based on forward
side scatter (FSC) and side scatter (SSC) parameters. The ﬂuorescence
emission of samples was analyzed with FL-1 (515 nm peak for FITC ﬂuores-
cence) and FL-2 (575 nm peak for PE ﬂuorescence) ﬁlters29. Results include
each immune cell-type represented as a percentage of the total cell popula-
tion, as well as the percentage of these speciﬁc immune cells that are acti-
vated. Data was averaged among the mice in each group (n¼ 5) and
averages compared across the groups time points.STATISTICAL ANALYSESStatistical analyses were done on all results using ANOVA, or repeat
analyses of variance and post hoc test Fischer’s PLSD or Student’s t test
with corrections for multiple comparisons all with the SPSS 12.0 software
packages. A P-value of 0.05 was considered statistically signiﬁcant.
ResultsDEVELOPMENT OF ANIMAL MODELThe powdered diet was provided ad lib and was well tol-
erated. There was no statistical difference in weight gain be-
tween any of the groups at any time (data now shown). The
GlcN consumed per day was determined from the total
weight of food consumed per day divided by ﬁve mice per
cage, and averaged 100 mgGlcN/kg/mouse/day 10 mg.
This resulted in a serum concentration of 24 mM (unpub-
lished data, Oegema).HISTOLOGYCompared to Day 0 [Fig. 1(A)], cartilage in papain-
injected joints was almost devoid of proteoglycans (PGs)
above the tidemark after 2 days [Fig. 1(B)]. Signiﬁcant dif-
ferences between the density of Safranin-O staining in the
papain-injected mice with and without oral GlcN were
seen at Day 14 [Fig. 1(C,D)]: Day 14 (no GlcN,
6492 1203 gray intensity per pixel/mm2) vs Day 14
(GlcN, 8354 1152 gray intensity per pixel/mm2) with
a P-value of 0.037. By 3 weeks, in the no GlcN group pro-
teoglycan content was still lower but not signiﬁcantly
(P< 0.08) and the 2 week and 3 week þGlcN knees were
the same (8105 1656 gray intensity per pixel/mm2)
[Fig. 1(E,F)]. This is consistent with the healing typically ob-
served at this level of papain damage in this model (26).PRO-INFLAMMATORY CYTOKINE LEVELS IN THE LIVER AND
SERUMWe next examined the mouse groups with a Bio-Rad Mul-
tiplex Cytokine Assay to determine if the papain-induced
joint damage modulated the levels of circulating pro-inﬂam-
matory cytokines and if this response was altered by oral
GlcN. Overall, the papain-injected groups receiving a normal
diet showed an increase in pro-inﬂammatory cytokine levels
(TNF-a, IL-1b, and IL-6), peaking signiﬁcantly at Day 7, rela-
tive to both the Day 0 group and the uninjected group receiv-
ing the GlcN diet at that same time point [Fig. 2(B,D,F)].
Interestingly, the papain-injected, GlcN groups had peak cy-
tokine levels at Day 2, exhibiting an overall accelerated and
potentiated acute-phase response to the papain injection.
Further, this elevation returned back to baseline levels
more quickly than the adjacent group receiving a normaldiet. Although MIP-1a showed signiﬁcant elevation in the pa-
pain-injected Day 2 group which received GlcN, the levels of
this cytokine did not change in any of the other groups
[Fig. 2(H)]. The groups receiving only GlcN did not show
any changes at any time. No signiﬁcant differences were
observed for any of the cytokines by Day 21.
The production of these same pro-inﬂammatory cytokines
was also monitored in the liver via real-time PCR to demon-
strate that the liver also reacts to the papain injection in the
knee joint with an acute-phase response and, given its prox-
imity to absorption (via the hepatic portal system), this re-
sponse can be modulated with oral GlcN [Fig. 2(A,C,E,G)].
Consistent with the proﬁles measured in the serum for the
cytokines of interest, a signiﬁcant increase (P< 0.05, deter-
mined using multivariate ANOVA) in all the cytokines mea-
sured was observed at Day 7 in the group injected with
papain and receiving a normal diet. A signiﬁcant reduction
in these same pro-inﬂammatory cytokine levels was
observed at Day 7 for the papain-injected mice receiving
GlcN (relative to the papain-injected, no GlcN mice). This re-
duction follows the same potentiation of the response in the
papain-injected Day 2 mice receiving GlcN observed in the
serum studies. These results further supports our observa-
tions that the GlcN-supplemented mice experience a more
rapid, yet ﬂeeting, acute-phase response that is more intense
at Day 2 relative to its counterpart (no GlcN) group. In agree-
ment with the serum studies, the groups receiving GlcN
alone also did not show any changes as compared to Day
0 or over time and no signiﬁcant differences were observed
for any of the cytokines by Day 21.FLOW CYTOMETRYMLNs were harvested from each mouse in all the groups.
Cells in the draining MLNs were isolated and labeled with
FITC- or R-PE-conjugated antibodies for ﬂow cytometry.
The percentage of different immune cell types of the total
population of cells in the MLNs was determined via ﬂow cy-
tometry. Neither papain injection, GlcN supplementation,
nor a combination of both seems to have altered the per-
centage of T cells, B cells, or granulocyte populations signif-
icantly (data not shown). The isolated cells were double
stained with a CD69 antibody to determine the activation
state of these cells and, interestingly, a similar pattern to
what was observed for the pro-inﬂammatory cytokines
was seen here (Fig. 3). The percentage of activated T cells,
B cells, and granulocytes increased from Day 0 and peaked
at Day 7 in the mice receiving only a papain injection,
whereas in the mice injected with papain and given oral
GlcN, a peak in activation levels was observed at Day 2
and decreased from there. By Day 21, all cell types, with
the exception of CD4 and Gr-1 labeled cells, returned to
levels that were measured for Day 0. CD4, a marker for T
helper cells, and Gr-1, a marker for granulocytes, continued
to show a signiﬁcant increase at Day 21 in the papain-in-
jected group receiving no GlcN over the papain-injected,
GlcN-supplemented group. The mice receiving only
GlcN did not show a signiﬁcant increase at any time points.
The cells expressing CD62L, a receptor for L-selectin, and
F4/80, a marker for macrophages, were present but too
variable to interpret (data not shown).
Discussion
In this study, we proposed that one of the mechanisms by
which oral GlcN acts is by altering the response of organs
Fig. 1. Representative histological sections of mouse patella after papain injection. Histological images of mouse patella captured from (A) Day
0 (no papain, no GlcN), (B) Day 2 (papain only), (C) Day 14 (papain only), (D) Day 14 (papain and oral GlcN diet), (E) Day 21 (papain only), (F)
Day 21 (papain and oral GlcN diet) sections. Safranin-O density (gray intensity per pixel/mm2) was quantiﬁed exclusively in the mid-zone
below the surface in the femoral weight-bearing region. Note: the bar represents 100 mm.
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draining MLN cells. To test this hypothesis, a mouse model
of joint damage and repair, adapted by van den Berg, was
employed26. In agreement with van den Berg’s ﬁndings, his-
tological sections of the mouse patella clearly showed that
there was rapid depletion of proteoglycans after receiving
6 mg of papain/knee. Proteoglycans, however, were almost
completely restored by Day 21 showing that the amount of
papain injected was a mild insult and at least as measured
by glycosaminoglycan this damage was repairable. There
was also a signiﬁcant difference in glycosaminoglycan den-
sity as measured by Safranin-O densities at 2 weeks be-
tween papain-injected knees of mice receiving a control
diet (no GlcN, 6492 1203 gray intensity per pixel/mm2)and those receiving GlcN (8354 1152 gray intensity per
pixel/mm2) with a P-value of 0.037 and n¼ 5. By 3 weeks,
the no GlcN group was a little lower and the 2 week and 3
week GlcN groups were the same. Therefore, papain-in-
jected knees of mice receiving oral GlcN had quicker recov-
ery of at least their proteoglycan than those not receiving
GlcN. This is similar to GlcN’s effect on glycosaminoglycan
recovery of cartilage in chymopapain-injected rabbit
knees12 and the preservation of glycosaminoglycan in the
anterior cruciate resection model in the rabbit13.
The degradation of cartilage components in OA has been
attributed to an imbalance, within the joint space, between
catabolic and anabolic factors, such as various cytokines,
matrix metalloproteinases (MMP), aggrecanases
Fig. 2. Representative data of pro-inﬂammatory cytokine measurements in the serum and liver. Real-time PCR was performed on liver tissue
from each mouse to measure pro-inﬂammatory cytokine levels (IL-1b, TNF-a, MIP-1a, and IL-6) in the liver and changes that might occur due
to papain injection and/or GlcN supplementation [Fig. 2(A, C, E, G)]. Samples were run in duplicate and averaged among the groups. Results
are shown as a fold difference as compared to the Day 0 group. Serum harvested from the different mouse groups was measured via a Bio-
Plex Mouse Cytokine Panel in order to evaluate the effect of papain injection and GlcN supplementation on pro-inﬂammatory cytokine pro-
duction [Fig. 2(B, D, F, H)]. Samples were run in duplicates and averaged among the groups. *P< 0.05 vs Day 0, **P< 0.05 vs papain
only group at same time point.
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motifs (ADAMTS) 4,-5), and tissue inhibitors of metallopro-
teinases30. Oral GlcN may alter this response by shortening
the duration of time these catabolic factors are elevated in
the system. In order to determine what types of factors
could cause PG synthesis to be suppressed in the cartilage
when exposed to serum from the papain-injected groups;
Bio-Plex cytokine assays were performed to measure the
levels of various acute-phase pro-inﬂammatory cytokines
(IL-1b, TNF-a, IL-6, MIP-1a, IL-12, GM-CSF, and IFN-g). In-
terestingly, in the papain-injected groups, GlcN supplemen-
tation caused a more rapid and ﬂeeting elevation of the
cytokines in the serum than the no GlcN group. Importantly
we were able to document that oral GlcN modulates the pro-
duction and duration of cytokine expression, the implica-
tions of these ﬁndings on the acute-response to joint
injury are provocative. Previous studies done by manyothers have suggested that GlcN may interfere with pro-
inﬂammatory cytokine action upon chondrocytes di-
rectly25,31,32. In rat chondrocytes 10 mM GlcN blocks
changes of approximately 73% of the 2813 genes whose
transcription was altered by IL-1-b stimulation. This super
physiological level of GlcN fully protected the chondrocytes
from IL-1-induced expression of inﬂammatory cytokines,
chemokines, and growth factors as well as proteins in-
volved in prostaglandin E2 and nitric oxide synthesis. It
also blocked the IL-1-induced expression of matrix-speciﬁc
proteases such as MMP-3, MMP-9, MMP-10, MMP-12, and
ADAMTS-117.
The increases in cytokine levels in the serum seen here
could be due to a combination of proteins from the site of
inﬂammation (the joint), as well as acute-phase signaling
and production from the liver and from other organs, such
as MLNs.
Fig. 3. T cell, B cell, and granulocyte activation states in the mesenteric lymph nodes. MLN cells from all groups were isolated and double
stained with R-PE-conjugated antibodies for all T cells (panel CD3þ), T cell subsets (CD4þ, CD8þ), B cells (CD45R/B220þ), or granulocytes
(Gr-1þ) and FITC-conjugated CD69 to determine activation state, incubated with SA-PE if the primary antibody was biotinylated, ﬁxed, and
counted on a ﬂow cytometer. Results are shown as the percentage of activated cells in the total speciﬁc cell population. Results were aver-
aged within the individual groups and these values were compared among the different groups. *P< 0.05 vs Day 0, **P< 0.05 vs papain only
group at same time point.
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ﬂammation of the joint. The same pro-inﬂammatory cyto-
kines measured in the serum were also measured in the
liver via real-time PCR and a similar trend was observed
in the liver as well. Cytokines, in the papain-injected GlcN
groups, were expressed at a higher level earlier (by
Day 2) and decreased to control (Day 0) levels quicker.
The primary response of the liver to inﬂammation is the ex-
pression of acute-phase proteins, and a number of cyto-
kines, including IL-1b, TNF-a, IL-6, MIP-1a which were
measured in this study, and hormones are involved in the
regulation of this response. The ability of the GlcN to mod-
ulate the magnitude and duration of the response to inﬂam-
mation by the liver may be one mechanism by which the
system responds to matrix damage of a joint.
Human monocytes from rheumatoid arthritis synovium
shown that cytokines, such as TNF-a and IL-1b, released
from macrophages, lead to differentiation of dendritic cellsinto antigen-presenting cells, that macrophages may carry
fragments of bacteria from mucosal surfaces of the body
to the joints, and local cytokine production by macro-
phages can activate B cells, T cells, and natural killer
cells33. Our results have demonstrated that GlcN supple-
mentation, after papain injection, altered the response of
immune cells in the MLNs, such as T- and B-lympho-
cytes, granulocytes, and macrophages. Oral GlcN, al-
though it did not alter the total percentage of the
various immune cells measured, it did accelerate the ac-
tivation of these immune cells. T- and B-lymphocytes
were activated as early as Day 2 in the papain, GlcN
group and this activation was seen to decrease by Day
7. However, the group receiving a papain injection and
a normal diet, showed a peak in activation at Day 7. Ac-
tivation of immune cells, such as dendritic cells and mac-
rophages aid in the release of pro-inﬂammatory cytokines,
such as TNF-a and IL-1b which were seen to increase at
1020 S. Panicker et al.: A mouse model of glucosamine actionthe same time points these immune cells were activated.
Therefore, these lymphocytes, in combination with our ob-
servation of the expression proﬁle of the liver, may be
a contributing source of where these cytokines originate
that we measured in the serum. Changes in the expres-
sion and release of these various pro-inﬂammatory cyto-
kines may also aid in mediating subtle changes in the
proﬁle and/or activation of inﬂammatory cells that are re-
cruited to the site of infection and thereby ﬁne-tune the in-
ﬂammatory response of the system. While we did ﬁnd
a GlcN effect because we did not measure activation in
other lymph nodes away from the gut we cannot tell if
the modulation of activation is related to exposure to
higher concentrations of GlcN or it more general.
This action is not unexpected. GlcN is an immunomodu-
lator. For example, in female C57BL/6 mice, GlcN will abro-
gate the acute, but not late, phase of experimental
autoimmune encephalomyelitis by inducing a Th2 re-
sponse34. Oral GlcN is protective in the early phases of ad-
juvant arthritis in the rat35. In vitro, GlcN suppresses the
activation of rat T-lymphocyte and dendritic cell activation
as well as allogenic mixed lymphocyte reactivity, in
a dose dependent manner36. In vivo, daily intravenous
GlcN prolonged allogenic cardiac allograft survival36.
The most likely mechanism for GlcN action is the con-
trol of gene expression via O-GlcNAc addition from
uridine di-phospho (UDP)-N-acetylglucosamine (UDP-
GlcNAc) to key regulatory proteins37,38. The liver experi-
ences substantially higher GlcN concentrations than
cartilage, the effect is more pronounced. Higher UDP-
GlcNAc levels results in increased O-peptidyl UDP-N-
acetylglucosamine Transferase (OGT) activity, which
catalyzes the addition of O-GlcNAc moieties to serine/
threonine residues of speciﬁc signaling proteins and tran-
scription factors, such as stromal-derived factor 1 (Sp1),
NF-kB, and RNA polymerase II; proteins with critical roles
in the control of gene expression and/or cellular physiol-
ogy37,38. In this regard, the addition of the O-GlcNAc moi-
eties to these critical signaling intermediates (directly
resultant from GlcN supplementation) would be analo-
gous to the changes induced by modulated kinase
cascades. In fact, O-GlcNAc modiﬁcations and phosphor-
ylation are known to function in several different capac-
ities, including a ‘‘Yin-Yang’’ control mechanism39. More
to point of this discussion, this regulation can have impor-
tant effects on the expression of speciﬁc cytokines rele-
vant to inﬂammation and the onset/progression of OA
such as down-regulate NF-kB signaling as well as protein
kinase C and phospholipase A2
40.
Overall, our ﬁndings highlight the necessity to further in-
vestigate what role GlcN plays in altering the signaling in
other organs that contribute to inﬂammation and the effect
this would have on the production of factors which could ul-
timately affect joint biology.
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